ProCE Banner Activity

A CML Patient With Elevated BCR-ABL at 3 Months: To Switch or Not to Switch?

Clinical Thought
Knowing when to switch treatment based on BCR-ABL levels is key to effective CML therapy.

Released: April 27, 2015

Expiration: April 25, 2016

Share

Faculty

Elias Jabbour

Elias Jabbour, MD

Assistant Professor
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Novartis Oncology

Faculty Disclosure

Primary Author

Elias Jabbour, MD

Assistant Professor
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Elias Jabbour, MD, has disclosed that he has received consulting fees from Ariad, Bristol-Myers Squibb, Pfizer, and Teva and funds for research support from Amgen, Ariad, and Pfizer.